[Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus].

Exenatid a jeho místo v lécbe diabetes mellitus 2. typu.

Publisher: Ambit Media Country of Publication: Czech Republic NLM ID: 0413602 Publication Model: Print Cited Medium: Print ISSN: 0042-773X (Print) Linking ISSN: 0042773X NLM ISO Abbreviation: Vnitr Lek Subsets: MEDLINE

Publication: 2010- : Brno : Ambit Media
Original Publication: 1973-<1994> : Praha : Avicenum

Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/*therapeutic use ; Peptides/*therapeutic use ; Venoms/*therapeutic use; Animals ; Blood Glucose/analysis ; Diabetes Mellitus, Type 2/blood ; Exenatide ; Glucagon-Like Peptide 1/physiology ; Glycated Hemoglobin/analysis ; Humans ; Hypoglycemic Agents/adverse effects ; Incretins/physiology ; Peptides/adverse effects ; Venoms/adverse effects

'Incretin effect' refers to increased insulin response to oral glucose as compared to i.v. glucose response. Incretin mimetics are a new class of antidiabetic drugs lowering hyperglycaemia. Incretin mimetics mimic the natural human hormones called 'incretins' with blood glucose regulating action. Exenatide is a synthetic analogue GLP-1 which is resistant to enzymatic degradation by DPP IV. Subcutaneously administered exenatide stimulates insulin secretion, suppresses glucagon secretion, slows down stomach evacuation and reduces the weight. Its administration is safe and the most frequent side effect is mild nausea.

59

0 (Blood Glucose)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
0 (Incretins)
0 (Peptides)
0 (Venoms)
89750-14-1 (Glucagon-Like Peptide 1)
9P1872D4OL (Exenatide)

Date Created: 20080718 Date Completed: 20080909 Latest Revision: 20221207

20221213

18630617